• Free shipping from $200
  • collecting affordable offers from best manufacturers worldwide
  • Special offers every week

Category: Press Releases

EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update

WALTHAM, Mass., March 02, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the twelve-month period ended December 31, 2017, and provided an update on recent corporate and operational…

Read More

Press Releases

EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update

WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (”EyeGate” or ”the Company”) today announced financial results for the year ended December 31, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, ”This year EyeGate reached critical turning points in the…

Read More

Press Releases

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

WALTHAM, Mass., May 16, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Steven Boyd has joined its board. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Steven Boyd to…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company will present at the upcoming H.C. Wainwright 20th Annual Global Investment Conference, being held on September 4-6, 2018 at the…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants

WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the pricing of an underwritten public offering of 1,176,470 shares of its common stock and…

Read More

Press Releases

EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that patient enrollment is complete in the next two pilot studies using the Hyaluronic Acid (HA) polymer for both photorefractive keratectomy (PRK)…

Read More

Press Releases

Eyegate Pharmaceuticals, Inc. Announces Closing of Initial Public Offering of Approximately $4,100,000 of Common Stock

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced initial public offering of 683,250 shares of its common stock at a price…

Read More

Press Releases

EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

WALTHAM, Mass., August 07, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, MA, July 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on…

Read More

Press Releases